The DOI matches its Crossref record.
Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma
Abstract
PURPOSE: To evaluate the response rate and impact on quality of life of vinorelbine given as cycles of 30 mg/m 2 weekly for 6 weeks to patients with malignant pleural mesothelioma. PATIENTS AND METHODS: Twenty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and three female patients; median age, 58 years [range, 29 to 77 years]). Seventeen patients had epithelioid tumors, two had sarcomatoid tumors, and 10 had biphasic tumors. The International Mesothelioma Interest Group staging system was used: one patient had stage Ib disease, 10 had stage II disease, eight had stage III disease, and 10 had stage IV disease. Patients were treated with weekly injections of vinorelbine 30 mg/m 2. A cycle consisted of six weekly injections. The new guidelines to evaluate the response to treatment in solid tumors were used. Responses were measured by spiral computed tomography scan. RESULTS: All twenty-nine patients had measurable disease and were assessed for response. There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%). The median number of vinorelbine injections was 12 (range, 2 to 30). Quality-of-life analyses showed a benefit for vinorelbine therapy. CONCLUSION: Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma. The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Kindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420
Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., Schmid, R., Stupp, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm093 · Cited by 320
de Perrot, M., Feld, R., Cho, B. C. J., Bezjak, A., Anraku, M., Burkes, R., Roberts, H., Tsao, M. S., Leighl, N., Keshavjee, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5604 · Cited by 291
Muers, M. F., Stephens, R. J., Fisher, P., Darlison, L., Higgs, C. M., Lowry, E., Nicholson, A. G., O'Brien, M., Peake, M., Rudd, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60727-8 · Cited by 260
Self-citation
Metadata
- Authors
- Steele, J. P. C., Shamash, J., Evans, M. T., Gower, N. H., Tischkowitz, M. D., & Rudd, R. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-01
- Volume
- 18
- Issue
- 23
- Pages
- 3912-3917
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1869777220
- Cited by
- 203
- References
- 0
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma. https://app.cochat.ai/papers/10.1200/jco.2000.18.23.3912
- The paper
- Steele, J. P. C., Shamash, J., Evans, M. T., Gower, N. H., Tischkowitz, M. D., & Rudd, R. M. (2000). Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.23.3912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.